Early safety check: does new drug mix safely with opioid treatments?
NCT ID NCT07314346
Summary
This early-stage study aims to see if a new antiviral drug combination (BEM/RZR) changes how the body processes common medications used for opioid withdrawal (buprenorphine/naloxone or methadone). It will involve 32 healthy volunteers who are already on stable doses of one of these withdrawal medications. The main goal is to measure drug levels in the blood to check for any unsafe interactions before testing in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER STUDY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atea Study Site
Overland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.